{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:54:17Z","timestamp":1697356457280},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1093\/jac\/dki277","type":"journal-article","created":{"date-parts":[[2005,8,23]],"date-time":"2005-08-23T00:13:58Z","timestamp":1124756038000},"page":"615-618","source":"Crossref","is-referenced-by-count":11,"title":["HCV\/HIV-coinfection\u2014is there a state of the art after APRICOT and RIBAVIC?"],"prefix":"10.1093","volume":"56","author":[{"given":"S.","family":"Mauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,8,22]]},"reference":[{"key":"key\n\t\t\t\t20171010172105_B1","doi-asserted-by":"crossref","unstructured":"Br\u00e4u N, Rodriguez-Torres M, Salvatore M et al. Control of HIV viral load through highly active antiretroviral therapy (HAART) slows down liver fibrosis progression in HIV\/HCV-coinfection and makes it the same as in HCV-monoinfection. In: Programs and Abstracts of the European Association for the Study of the Liver, Berlin 2004. Abstract 91, p 23. European Association for the Study of the Liver, Geneva, Switzerland.","DOI":"10.1016\/S0168-8278(04)90091-8"},{"key":"key\n\t\t\t\t20171010172105_B2","unstructured":"Eyster ME, Diamondstone LS, Lien JM et al. Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with human immunodeficiency virus. A multicenter hemophilia cohort study. J Acq Immunodef Syndr1993; 6: 602\u201310."},{"key":"key\n\t\t\t\t20171010172105_B3","doi-asserted-by":"crossref","unstructured":"Poynard T, Mathurin P, Lai CL et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol2003; 38: 257\u201365.","DOI":"10.1016\/S0168-8278(02)00413-0"},{"key":"key\n\t\t\t\t20171010172105_B4","unstructured":"Rockstroh JK, Spengler U, Sudhop T et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol1996; 91: 2563\u20138."},{"key":"key\n\t\t\t\t20171010172105_B5","doi-asserted-by":"crossref","unstructured":"Benhamou Y, DeMartinio V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology2001; 34: 283\u20137.","DOI":"10.1053\/jhep.2001.26517"},{"key":"key\n\t\t\t\t20171010172105_B6","doi-asserted-by":"crossref","unstructured":"Qurishi N, Kreuzberg C, L\u00fcchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet2003; 362: 1708\u201313.","DOI":"10.1016\/S0140-6736(03)14844-1"},{"key":"key\n\t\t\t\t20171010172105_B7","doi-asserted-by":"crossref","unstructured":"Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy. J Infect Dis2005; in press.","DOI":"10.1086\/432762"},{"key":"key\n\t\t\t\t20171010172105_B8","doi-asserted-by":"crossref","unstructured":"Lewden C, Salmon D, Morlat P et al. Causes of deaths among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemol2005; 34: 121\u201330.","DOI":"10.1093\/ije\/dyh307"},{"key":"key\n\t\t\t\t20171010172105_B9","doi-asserted-by":"crossref","unstructured":"Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med2004; 351: 438\u201350.","DOI":"10.1056\/NEJMoa040842"},{"key":"key\n\t\t\t\t20171010172105_B10","doi-asserted-by":"crossref","unstructured":"Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA2004; 292: 2839\u201348.","DOI":"10.1001\/jama.292.23.2839"},{"key":"key\n\t\t\t\t20171010172105_B11","doi-asserted-by":"crossref","unstructured":"Hoggard PG, Kewn S, Barry MG et al. Effects of drugs on 2\u2032,3\u2032-dideoxy-2\u2032,3\u2032-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother1997; 41: 1231\u20136.","DOI":"10.1128\/AAC.41.6.1231"},{"key":"key\n\t\t\t\t20171010172105_B12","doi-asserted-by":"crossref","unstructured":"Vogt MW, Hartshorn KL, Furman PA et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science1987; 235: 1376\u20139.","DOI":"10.1126\/science.2435003"},{"key":"key\n\t\t\t\t20171010172105_B13","doi-asserted-by":"crossref","unstructured":"Mauss S, Valenti W, DePamphilis J et al. Risk factors for hepatic decompensation in patients with HIV\/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS2004; 18: F21\u20135.","DOI":"10.1097\/00002030-200409030-00002"},{"key":"key\n\t\t\t\t20171010172105_B14","doi-asserted-by":"crossref","unstructured":"Laguno M, Murillas J, Blanco JL et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients. AIDS2004; 18: F27\u201334.","DOI":"10.1097\/00002030-200409030-00003"},{"key":"key\n\t\t\t\t20171010172105_B15","unstructured":"Voigt E, Schulz C, Klausen G et al. Pegylated interferon \u03b1 2b plus ribavirin for treatment of chronic hepatitis C in HIV-coinfected patients: a German multicenter trial. In: First International Workshop on HIV and Hepatitis Co-Infection, Amsterdam, 2004. Abstract CI15. Virology Education, Utrecht, The Netherlands."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/4\/615\/2307851\/dki277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T04:45:50Z","timestamp":1586407550000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/4\/615\/769292\/HCVHIVcoinfectionis-there-a-state-of-the-art-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,22]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,8,22]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki277","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,10]]},"published":{"date-parts":[[2005,8,22]]}}}